Get the Stockscreener App
48.09
1.43%
-0.70
After Hours:
48.15
0.06
+0.12%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $48.09, with a volume of 12.31M.
It is down -1.43% in the last 24 hours and down -4.90% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$48.79
Open:
$48.49
24h Volume:
12.31M
Relative Volume:
0.85
Market Cap:
$97.87B
Revenue:
$47.64B
Net Income/Loss:
$5.42B
P/E Ratio:
18.01
EPS:
2.67
Net Cash Flow:
$13.09B
1W Performance:
+2.56%
1M Performance:
-4.90%
6M Performance:
-18.06%
1Y Performance:
+15.13%
1-Day Range:
$47.65
$48.93
1-Week Range:
$46.10
$48.93
52-Week Range:
$39.35
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
48.09 | 95.42B | 47.64B | 5.42B | 13.09B | 2.67 |
|
LLY
Lilly Eli Co
|
750.78 | 651.06B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
154.42 | 368.73B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
187.25 | 328.06B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.94 | 223.60B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
70.91 | 312.99B | 43.59B | 15.04B | 10.74B | 3.3766 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Super deal for BioNTech – BMS licenses potential blockbuster for €10bn - European Biotechnology Magazine
Bristol Myers to pay $1.5 billion upfront for BioNTech cancer drug partnership - MSN
BioNTech (NasdaqGS:BNTX) Enters Global Co-Development Agreement With Bristol Myers Squibb - simplywall.st
Bristol Myers To Pay Up To $11.1B To BioNTech To Co-Develop, Commercialize Investigational Cancer Drug - MSN
Bristol Myers Collaborates With BNTX for Oncology Candidate - The Globe and Mail
Epigenetics Market Anticipated to Achieve 11.8% CAGR - GlobeNewswire Inc.
Bristol-Myers Squibb (NYSE:BMY) Collaborates With BioNTech For Antibody Development In Cancer Treatment - simplywall.st
Bristol Myers Squibb, BioNTech partner on $11B cancer drug deal - NJBIZ
BioNTech and BMS partner to advance oncology deal worth over $10 billion - European Pharmaceutical Review
American Bristol-Myers acquires license for innovative drug from German BioNTech for $11.1 billion - AKM.RU
BioNTech, Bristol Myers Squibb Team Up on China-Made Cancer Drug - Yicai Global
BMS Buys Into BioNTech Bispecific Antibody, Putting Up $1.5B to Collaborate in Multiple Cancers - MedCity News
Bristol-Myers Squibb Company and BioNTech SE Partner to Advance Next-Gen Cancer Therapies - Insider Monkey
Biontech trades half of bispecific BNT-327 to BMS for potential $11B+ - BioWorld MedTech
Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space - insights.citeline.com
Bristol Myers' new cancer partnership is promising, but doesn't change our stance on the stock yet - CNBC
Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy - The Economic Times
Bristol Myers (BMY) Deal Seen as Highly Positive for BioNTech | - GuruFocus
BioNTech SE’s Strategic Partnership with Bristol Myers Squibb Boosts Financial Prospects and Reinforces Buy Rating - TipRanks
Bristol-Myers (BMY) Licenses BioNTech’s Immunotherapy in $11 billion Deal - Insider Monkey
Bristol Myers (BMY) Joins BioNTech in Promising Co-Development A - GuruFocus
Bristol Myers (BMY) and BioNTech Strike $11.1B Licensing Deal for Cancer Therapy - GuruFocus
BMS acquires rights to BioNTech’s bispecific antibody candidate BNT327 - The Pharma Letter
BMS outlays $11bn to join BioNTech’s development of bispecific cancer drug - Pharmaceutical Technology
Raymond James maintains market perform rating on Bristol Myers Squibb stock - Investing.com Australia
Cancer Moonshot: Bristol-Myers Just Dropped $11 Billion on a Single BioNTech Drug - GuruFocus
Citi maintains neutral rating on Bristol-Myers Squibb stock By Investing.com - Investing.com India
Bristol-Myers to Pay $11 Billion to License Cancer Drug - Yahoo Finance
Watch Bristol-Myers to Pay $11 Billion to License Cancer Drug - Bloomberg.com
BioNTech Stock Jumps on Bristol Myers Squibb Cancer Drug Collaboration - Investopedia
Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug - Yahoo Finance
Citi maintains neutral rating on Bristol-Myers Squibb stock - Investing.com
BMS Commits up to $11B+ To Work With BioNTech on Solid Tumor Bispecific - BioSpace
Bristol Myers: signs global agreement with BioNTech - marketscreener.com
Bristol Myers inks $11B BioNTech deal to join bispecific gold rush, leaping ahead of Merck and Pfizer - Fierce Biotech
Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race - MarketWatch
Bristol-Myers to Pay BioNTech Up to $11.1 Billion in Cancer Deal - Bloomberg
Bristol Myers Squibb Partners with BioNTech in $1.5 Billion Deal to Develop Bispecific Cancer Drug Targeting PD1 and VEGF - geneonline.com
BioNTech, Bristol Myers partner to co-develop BNT327 - TipRanks
BioNTech Partners with Bristol Myers Squibb to Co-Develop Bispecific Antibody Drug BNT327 - marketscreener.com
BioNTech and Bristol Myers Squibb Partner for Global Development of BNT327 - TipRanks
Bristol Myers to help develop cancer drug in BioNTech partnership - BusinessLIVE
BioNTech soars 15% on cancer drug deal with Bristol Myers - StreetInsider
BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb - WSJ
BioNTech soars 15% on cancer drug deal with Bristol Myers By Investing.com - Investing.com Nigeria
BioNTech, Bristol Myers Squibb to Co-Develop Bispecific Cancer Treatment - marketscreener.com
BioNTech soars premarket amid Bristol Myers deal - breakingthenews.net
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types | - GuruFocus
BioNTech and Bristol Myers Squibb enter up to $11.1B cancer drug collaboration - Investing.com Australia
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types - The Manila Times
Bristol Myers allies with BioNTech on bispecific cancer drug - BioPharma Dive
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):